Zealand Pharma A/S/€ZEAL
1D1W1MYTD1Y5YMAX
Capital at risk
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.
- Ticker
- €ZEAL
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 578
- Headquarters
- Søborg, Denmark
- Website
- www.zealandpharma.com
ZEAL Metrics
BasicAdvanced
€2.6B
7.35
€5.15
0.59
-
Price and volume
Market cap
€2.6B
Beta
0.59
52-week high
€74.26
52-week low
€30.50
Average daily volume
393K
Financial strength
Current ratio
13.979
Quick ratio
13.755
Long term debt to equity
0.021
Total debt to equity
0.023
Interest coverage (TTM)
85.26%
Profitability
EBITDA (TTM)
310.888
Gross margin (TTM)
100.00%
Net profit margin (TTM)
59.02%
Operating margin (TTM)
49.68%
Effective tax rate (TTM)
3.49%
Revenue per employee (TTM)
€1,074,170
Management effectiveness
Return on assets (TTM)
7.81%
Return on equity (TTM)
16.31%
Valuation
Price to earnings (TTM)
7.348
Price to revenue (TTM)
4.292
Price to book
1.09
Price to tangible book (TTM)
1.14
Price to free cash flow (TTM)
-10.885
Free cash flow yield (TTM)
-9.19%
Free cash flow per share (TTM)
-3.48
Growth
Revenue change (TTM)
-49.02%
Earnings per share change (TTM)
-58.86%
3-year revenue growth (CAGR)
270.01%
10-year revenue growth (CAGR)
37.73%
3-year earnings per share growth (CAGR)
25.71%
10-year earnings per share growth (CAGR)
19.13%
Bulls say / Bears say
Zealand Pharma entered into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for its economic interests in rusfertide, converting a future potential royalty stream into immediate capital for strategic priorities. (stockopedia.com)
In June 2026, petrelintide's mid-stage trial showed only 1.5% patient discontinuations due to gastrointestinal side effects, indicating a favorable tolerability profile versus existing GLP-1 therapies. (finance.yahoo.com)
Boehringer's Phase 3 data for survodutide, licensed from Zealand, demonstrated an average 16.6% weight loss after 76 weeks and significant reductions in visceral and liver fat, underscoring Zealand's diversified pipeline value. (finance.yahoo.com)
Zealand Pharma's H1 2026 revenue fell sharply from prior year levels and operating profit declined by over 50% year-on-year, reflecting lump-sum license revenue volatility. (stockopedia.com)
Survodutide's Phase 3 trial also reported high discontinuation rates, with a quarter of patients quitting due to side effects, raising concerns over its commercial viability. (finance.yahoo.com)
The company maintained its 2026 guidance for collaboration operating expenses at DKK 2.7–3.3 billion despite lower revenue, highlighting continued high cash burn and margin pressure. (stockopedia.com)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.